Furthermore, pharmaceutical approaches that target mitochondrial dynamics have been developed for the treatment of neurodegenerative diseases and type 2 diabetes, including mitochondrial division inhibitor-1 (mdivi-1, a Drp1-specific inhibitor), dynasore, P110 and 15-oxospiramilactone, etc. (53, 65, 104). The gene discussed is DNM1L; the disease is type 2 diabetes mellitus.